全文获取类型
收费全文 | 17441篇 |
免费 | 1957篇 |
国内免费 | 1237篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 261篇 |
妇产科学 | 176篇 |
基础医学 | 1721篇 |
口腔科学 | 272篇 |
临床医学 | 2608篇 |
内科学 | 2326篇 |
皮肤病学 | 162篇 |
神经病学 | 750篇 |
特种医学 | 650篇 |
外国民族医学 | 7篇 |
外科学 | 1307篇 |
综合类 | 3583篇 |
现状与发展 | 9篇 |
一般理论 | 2篇 |
预防医学 | 1663篇 |
眼科学 | 310篇 |
药学 | 2068篇 |
29篇 | |
中国医学 | 1383篇 |
肿瘤学 | 1294篇 |
出版年
2024年 | 101篇 |
2023年 | 385篇 |
2022年 | 823篇 |
2021年 | 1093篇 |
2020年 | 875篇 |
2019年 | 633篇 |
2018年 | 652篇 |
2017年 | 640篇 |
2016年 | 619篇 |
2015年 | 886篇 |
2014年 | 1137篇 |
2013年 | 1027篇 |
2012年 | 1443篇 |
2011年 | 1587篇 |
2010年 | 1181篇 |
2009年 | 963篇 |
2008年 | 966篇 |
2007年 | 910篇 |
2006年 | 862篇 |
2005年 | 728篇 |
2004年 | 445篇 |
2003年 | 452篇 |
2002年 | 339篇 |
2001年 | 305篇 |
2000年 | 292篇 |
1999年 | 234篇 |
1998年 | 162篇 |
1997年 | 155篇 |
1996年 | 131篇 |
1995年 | 112篇 |
1994年 | 80篇 |
1993年 | 55篇 |
1992年 | 55篇 |
1991年 | 73篇 |
1990年 | 52篇 |
1989年 | 45篇 |
1988年 | 26篇 |
1987年 | 36篇 |
1986年 | 20篇 |
1985年 | 14篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1974年 | 2篇 |
1971年 | 2篇 |
1968年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
目的 探讨腰硬联合(CSEA)及患者自控镇痛(PCEA)对产程及分娩结局的影响。方法 随机选取2014年1~12月足月待产、无妊娠合并症和并发症初产妇996例,其中503例产妇于活跃期实施CSEA+PCEA镇痛(分娩镇痛组),493例未行分娩镇痛(对照组),分别记录并比较两组产妇各产程时间、子宫收缩、镇痛效果、运动神经阻滞程度、产程中缩宫素的使用率、产后出血率、羊水Ⅲ度污染率、新生儿Apgar评分、产钳助产和剖宫产率。结果 分娩镇痛组第一产程、第二产程较对照组有所延长,差异有统计学意义(P<0.05);第三产程无明显改变;子宫收缩力减弱;分娩镇痛组较对照组镇痛效果显著,差异有统计学意义(P<0.05);运动阻滞程度低;缩宫素使用率、产后出血率、羊水Ⅲ度污染率、及新生儿Apgar评分及产钳助产和剖宫产率两组比较,差异均无统计学意义(P>0.05)。结论 腰硬联合分娩镇痛可能会使第一产程、第二产程延长,对子宫收缩力有一定的影响,但并未增加缩宫素的使用率及产钳助产和剖宫产率,其镇痛效果显著,运动阻滞程度低,对分娩结局无不良影响。 相似文献
3.
4.
目的:通过对羽毛球爱好者的问卷调查,结合羽毛球项目的运动特点,分析常见的运动损伤部位及其发病原因、处理方法以及预防措施.
方法:调查于2005—03/11在成都医学院体育教研室羽毛球俱乐部完成,对156名羽毛球爱好者进行运动损伤情况凋查,均自愿参加调查。采用问卷调查和专家访谈相结合的方法,主要结合羽毛球项目的运动特点,调查运动损伤的患病率、损伤类型及其受伤原因,分析其常用的处理方法及预防措施。
结果:共发放问卷156份,收回内容详实问卷156份。(1)损伤患病率:运动损伤患病率为78,84%。(2)损伤类型:156名羽毛球爱好者中急性损伤占52、56%,慢性损伤占26,28%。最容易受伤的手腕处受伤患病率为37.39%,其次是肩袖受伤患病率为30.89%。(3)受伤原因:技术动作不规范是运动损伤最主要的原因,占72,35%,而准备活动不充分和身体疲劳分别占63、41%和22.76%.
结论:为有效预防手腕和肩袖损伤,应加强局部肌肉力量训练等防治措施;注意学习和掌握正确的动作技术要领,做好充分的准备活动是十分必要的. 相似文献
5.
背景:对于脊椎以外的骨折而言,补充口服维生素D的预防作用和用量仍无定论。
目的:评估补充维生素D在预防老年髋骨骨折和非脊椎骨折方面的效果。
数据来源:使用MEDLINE、Cochrance对照试验记录(1960~2005年)以及EMBASE(1991-2005年),对英文和非英文文章进行系统回顾。通过与临床专家接触,通过检索美国社会骨和骨矿研究协会提供的参考文献和摘要(1995~2004年).进一步寻找更多的研究。检索词包括随机对照试验(randomized controlled trial,RCT)、临床对照试验、随机分配、双盲法、维生素D3、维生素D2;25-羟基维生素D、骨折、人类、老年、摔倒和骨密度。
研究选取:纳入的研究仅限于口服补充维生素D(维生素D3、维生素D2、补钙或不补钙)与补钙或安慰剂比较的双盲RCTs。试验于检查髋部骨折或非脊椎骨折的老年人(年龄≥60岁)中进行。数据提取:两位作者根据预先规定独立提取相关数据,其中包括研究质量指标。
数据综合:所有的汇总分析均以随机效应模型为基础。5项有关髋部骨折的RCTs(n=9294)和7项有关非脊椎骨折危险的RCTs(n=9820)符合我们的纳入标准。所有试验均使用了维生素D3。对髋部和非脊椎骨折预防研究的异质性亦进行观察,用低剂量(400IU/d)和高剂量(700~800IU/d)分别合并RCTs后异质性消失。与补钙或安慰剂相比,每天服700~800IU的维生素D可使髋部骨折的相对危险(relative risk,aa)下降26%(3项RCTs共计5572人;RR,0.74;95%可信区间[confidence interval,CI],0.61~0.88),使非脊椎骨折的相对危险下降23%(5项RCTs共计6098人;RR,0.77;95%CI,0.68~0.87)。每天服400IU的维生素D(2项RCTs共计3722人;髋部骨折RR,1.15;95%CI,0.88~1.50;非脊椎骨折RR,1.03;95%CI,0.86—1.24)未见明显获益。
结论:口服补充维生素D(700~800IU/d)可以降低尚能活动的老人或慈善机构收容的老年人发生髋部骨折和脊椎以外骨折的危险,每天口服400IU维生素D并不足以预防骨折。 相似文献
6.
项韧带骨化相关因素及其组织学变化 总被引:1,自引:0,他引:1
目的:探讨脊髓型颈椎病患者项韧带骨化的相关因素及其组织学改变特点.方法:将45例脊髓型颈椎病患者根据项韧带有无骨化分为两组,观察并统计两组患者的年龄、性别组成、颈椎椎间退变和颈椎稳定性情况,对各指标与项韧带骨化的关系进行相关性分析,同时观察项韧带骨化的组织学改变.结果:统计分析表明,项韧带骨化和颈椎椎间退行性改变及颈椎不稳定之间具有相关性(P<0.05);同时还与患者年龄、性别组成有相关性(P<0.05).项韧带骨化的组织学改变以软骨内化骨为主.结论:项韧带骨化与颈椎退行性改变及颈椎椎间关节不稳定具有相关性,组织学改变以软骨内化骨为主. 相似文献
7.
Yubin Miao Said D Figueroa Darrell R Fisher Herbert A Moore Richard F Testa Timothy J Hoffman Thomas P Quinn 《Journal of nuclear medicine》2008,49(5):823-829
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment. 相似文献
8.
Yulu Miao Mingxia Zhang Yulin Nie Wan Zhao Bin Huang Zhengming Jiang Shaoxiong Yu Zhibin Huang Hongjin Fu 《中国神经再生研究》2007,2(2):126-128
BACKGROUND: Besides local changes of cranial parenchymal cells, hemorrhage, etc., severe traumatic brain injuries also cause the changes of total body fluid and various functions, and the changes of lymphocytes and T lymphocyte subsets should be paid more attention to. OBJECTIVE: To reveal the changing laws of T lymphocyte subsets after severe traumatic brain injury, and compare with mild to moderate brain injury. DESIGN: A comparative observation. SETTINGS: Department of Neurosurgery, Longgang District Buji People's Hospital of Shenzhen City; Central Laboratory of Shenzhen Hospital of Prevention and Cure for Chronic Disease. PARTICIPANTS: All the subjects were selected from the Department of Neurosurgery, Longgang District Buji People's Hospital of Shenzhen City from August 2002 to August 2005. Thirty patients with severe brain injury, whose Glasgow coma score (GCS) was ≤ 8 points, were taken as the experimental group, including 21 males and 9 females, aging 16 - 62 years. Meanwhile, 30 patients with mild traumatic brain injury were taken as the control group (GCS ranged 14- 15 points), including 18 males and 12 females, aging 15 -58 years. All the subjects were in admission at 6 hours after injury, without disease of major organs before injury Informed consents were obtained from all the patients or their relatives. METHODS: (1) The T lymphocytes and the subsets in peripheral blood were detected with immunofluorescent tricolor flow cytometry at l, 3, 7 and 14 days after injury in both groups. (2) The conditions of pulmonary infections were observed at 4 days after injury. The differences of measurement data were compared with the t test. MAIN OUTCOME MEASURES: Changes of T lymphocytes subsets at 1 - 14 days after severe and mild or moderate traumatic injury. RESULTS: Finally, 28 and 25 patients with mild to moderate traumatic brain injury, whereas 25 and 21 patients with severe traumatic brain injury were analyzed at 7 and 14 days respectively, and the missed ones died due to the development of disease. (1) Changes of T lymphocyte subsets: At 1 and 3 days after injury, CD3, CD4, CD8, CD4/CD8 began to decrease, whereas CD8 increased in the experimental group, which were very significantly different from those in the control group (t =2.77 - 3.26, P 〈 0.01), and began to recover at 7 days, which were significantly different from those in the control group (t = 2.06 - 2.24, P 〈 0.05), and generally recovered to the normal levels at 14 days (P 〉 0.05). (2) Conditions of pulmonary infections: At 4 days after injury, the rate of pulmonary infection was significantly different between the experimental group and control group [73% (22/30), 0, x2=37.29, P 〈 0.01]. CONCLUSION: Patients with severe traumatic brain injury suffer from damages of cellular immune function at early period (within 7 days), and they are easily to be accompanied by pulmonary infections. 相似文献
9.
Ziprasidone (Geodone), a novel atypical antipsychotic agent, is recently approved for the treatment of schizophrenia. It undergoes extensive metabolism in preclinical species and humans after oral administration, and only a very small amount of administered dose is excreted as unchanged drug. In vitro studies using human liver microsomes have shown that the oxidative metabolism of ziprasidone is mediated primarily by CYP3A4. However, coadministration of ziprasidone with ketoconazole, a CYP3A4 inhibitor, showed only a modest increase in its exposure. Therefore, in vitro metabolism of ziprasidone was investigated in hepatic cytosolic fractions to further understand its clearance mechanisms in preclinical species and humans. The major metabolite from incubation of ziprasidone in cytosolic fractions of rat, dog, and human was characterized by liquid chromatography-tandem mass spectrometry and found to be the product of reductive cleavage. Derivatization and hydrogen/deuterium exchange were used to deduce that the addition of two hydrogen atoms had occurred at the benzisothiazole moiety. Further studies to determine the enzyme involved in the formation of this metabolite are currently in progress. The identification of this novel metabolite in cytosol has clarified the clearance mechanism of ziprasidone in humans and preclinical species. 相似文献
10.